The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells

Drug Metabolism and Disposition

Volumn 28, Issue 9, 2000, Pages 1058-1062

  Washington, Carla B ^a   Wiltshire, Hugh R ^b   Man, Martha ^a   Moy, Tina ^a   Harris, Steve R ^b   Worth, Eric ^b   Weigl, Paul ^c   Liang, Zhenmin ^c   Hall, David ^d   Marriott, Lorraine ^d   Blaschke, Terrence F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBON 14; GLYCOPROTEIN P; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TRITIUM;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG PENETRATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS INHIBITION;

ANIMALS; AREA UNDER CURVE; BRAIN; CARBON RADIOISOTOPES; HIV PROTEASE INHIBITORS; HUMANS; MALE; MICE; MICE, MUTANT STRAINS; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SAQUINAVIR; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0033827147     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell
2. What have we learnt thus far from mice with disrupted P-glycoprotein genes?
3. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
6. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans
7. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
8. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4
9. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
10. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
11. Safety and activity of saquinavir in HIV infection
12. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
13. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor
14. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity
15. Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection
16. Saquinavir soft-gel capsule formulation: A review of its use in patients with HIV infection
17. Neurological complications of HIV infection
18. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors
19. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
20. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
21. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
22. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
23. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
24. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells
25. Cellular localization of the multidrug resistance gene product in normal human tissues
26. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
27. The synthesis of labelled forms of saquinavir